Interferon-induced ISG15 conjugation plays an important antiviral role against several viruses, including influenza viruses. The NS1 protein of influenza B virus (NS1B) specifically binds only human and nonhuman primate ISG15s and inhibits their conjugation. To elucidate the structural basis for the sequence-specific recognition of human ISG15, we determined the crystal structure of the complex formed between human ISG15 and the N-terminal region of NS1B (NS1B-NTR). The NS1B-NTR homodimer interacts with two ISG15 molecules in the crystal and also in solution. The two ISG15-binding sites on the NS1B-NTR dimer are composed of residues from both chains, namely residues in the RNA-binding domain (RBD) from one chain, and residues in the linker between the RBD and the effector domain from the other chain. The primary contact region of NS1B-NTR on ISG15 is composed of residues at the junction of the N-terminal ubiquitin-like (Ubl) domain and the short linker region between the two Ubl domains, explaining why the sequence of the short linker in human and nonhuman primate ISG15s is essential for the species-specific binding of these ISG15s. In addition, the crystal structure identifies NS1B-NTR binding sites in the N-terminal Ubl domain of ISG15, and shows that there are essentially no contacts with the C-terminal Ubl domain of ISG15. Consequently, NS1B-NTR binding to ISG15 would not occlude access of the C-terminal Ubl domain of ISG15 to its conjugating enzymes. Nonetheless, transfection assays show that NS1B-NTR binding of ISG15 is responsible for the inhibition of interferoninduced ISG15 conjugation in cells.
Interferon-induced ISG15 conjugation plays an important antiviral role against several viruses, including influenza viruses. The NS1 protein of influenza B virus (NS1B) specifically binds only human and nonhuman primate ISG15s and inhibits their conjugation. To elucidate the structural basis for the sequence-specific recognition of human ISG15, we determined the crystal structure of the complex formed between human ISG15 and the N-terminal region of NS1B (NS1B-NTR). The NS1B-NTR homodimer interacts with two ISG15 molecules in the crystal and also in solution. The two ISG15-binding sites on the NS1B-NTR dimer are composed of residues from both chains, namely residues in the RNA-binding domain (RBD) from one chain, and residues in the linker between the RBD and the effector domain from the other chain. The primary contact region of NS1B-NTR on ISG15 is composed of residues at the junction of the N-terminal ubiquitin-like (Ubl) domain and the short linker region between the two Ubl domains, explaining why the sequence of the short linker in human and nonhuman primate ISG15s is essential for the species-specific binding of these ISG15s. In addition, the crystal structure identifies NS1B-NTR binding sites in the N-terminal Ubl domain of ISG15, and shows that there are essentially no contacts with the C-terminal Ubl domain of ISG15. Consequently, NS1B-NTR binding to ISG15 would not occlude access of the C-terminal Ubl domain of ISG15 to its conjugating enzymes. Nonetheless, transfection assays show that NS1B-NTR binding of ISG15 is responsible for the inhibition of interferoninduced ISG15 conjugation in cells. V irus infection of animal cells leads to the production of interferon-α/β (IFN-α/β), which in turn induces the synthesis of a large number of proteins, many of which exert antiviral activity (1) . One protein that is strongly induced by IFN-α/β is ISG15, which is composed of two ubiquitin-like (Ubl) domains that are connected by a short 5-residue interdomain linker region (2) . The C-terminal Ubl domain (C-Ubl) contains a LRLRGG sequence at the C terminus that is conjugated to target proteins by the sequential action of three enzymes that are also induced by IFN-α/β: The E1 enzyme Ube1L activates ISG15, followed by the transfer of ISG15 to the E2 conjugating enzyme, UbcH8 (3) (4) (5) . Herc5, which is the major E3 ligase, then functions in the conjugation of ISG15 to target proteins (6, 7) .
IFN-induced ISG15 conjugation plays an important antiviral role against several viruses, including influenza A and B viruses, Sindbis virus, herpes simplex virus type 1, murine gammaherpes virus, Japanese encephalitis virus, and vaccinia virus (8) (9) (10) (11) (12) (13) . A major mechanism by which ISG15 conjugation inhibits one of these viruses, influenza A virus, has been identified (10, 14) . Specifically, the ISG15 conjugation system targets a viral protein, the NS1 protein (NS1A), which is responsible for countering key components of the host antiviral system. The conjugation of ISG15 to the NS1A protein results in a loss of one or more of its functions, thereby inhibiting virus replication. It is not known whether a similar loss-of-function mechanism occurs with the other viruses.
The first evidence for an antiviral function for ISG15 conjugation was the finding that the NS1 protein of influenza B virus (NS1B) binds ISG15 and blocks its conjugation, suggesting that ISG15 conjugation inhibits influenza B virus replication (5) . Consistent with this conclusion, ISG15 and Ube1L knockout mice were shown to be more susceptible to influenza B virus replication (15) . However, these results raised another issue: Why was the NS1B protein unable to protect influenza B virus from the antiviral effects of ISG15 conjugation in wild-type mice? The issue was resolved by the demonstration that the NS1B protein does not bind mouse ISG15 (16, 17) , and in fact binds only human and nonhuman primate ISG15 molecules (16) . In addition, in infected cells the NS1B protein relocalizes only human and nonhuman primate ISG15s from the cytoplasm to nuclear compartments known as splicing or S35 speckles (16) .
These results provide one explanation for the well-known restriction of influenza B virus to humans. In contrast, influenza A viruses have been isolated from a wide variety of avian and mammalian species, and wild aquatic birds are the known reservoir for influenza A viruses that infect avian and mammalian species (18, 19) . In addition, with influenza A virus, reassortants between human and avian strains result in new pandemic viruses. Comparable reassortants with influenza B viruses cannot occur because of the restriction of influenza B virus to humans. Hence, it is important to understand the features of influenza B that limit the range of species that it can infect.
The molecular basis for the species specificity of ISG15 binding by the NS1B protein has been investigated by mutagenesis experiments (16) . Surprisingly, the small 5-residue interdomain linker region in human ISG15 plays an essential role in the species-specific binding by the NS1B protein. Only human and nonhuman primate ISG15 molecules have a sequence in the interdomain linker region that enables binding to the NS1B protein (16) . These results, however, could not distinguish between roles of the linker sequence in either (i) defining an interdomain orientation that is suitable for the binding of the N-terminal Ubl domain (N-Ubl) to the NS1B protein, or (ii) providing specific interactions between human/nonhuman primate ISG15 and the NS1B protein. A clear understanding of the molecular basis of this recognition specificity requires a 3D structure of the complex between ISG15 and NS1B.
The residues in the NS1B protein that directly interact with human ISG15 have also not yet been definitively identified. The NS1B protein, a 281 amino-acid protein, is composed of an Nterminal RNA-binding domain (RBD, residues 1-90) and an effector domain (ED, residues 120-281), connected by an interdomain linker region (residues 91-119). ISG15 binds to the N-terminal domain region (NTR, defined here as residues 1-103) of the NS1B protein, which includes the RBD and the first 13 residues of the interdomain linker (20, 21) . We have shown that the 94-103 region of the NS1B protein is required for ISG15 binding (5) and that simultaneous triple mutation of E29/Y31/R33 to alanines affects ISG15 binding (20) . However, a 3D structure of the complex is required to fully characterize the binding interface and to distinguish the roles of these residues in interactions with ISG15 relative to their roles in stabilizing the structure of NS1B itself.
Another key question is how the binding of ISG15 by the NS1B protein results in the inhibition of IFN-induced ISG15 conjugation. In vitro assays have shown that the C-Ubl of human ISG15 alone supports efficient activation by the E1 Ube1L enzyme, as well as efficient transfer to the E2 UbcH8 enzyme (21) . In addition, transfection experiments have recently shown that the C-Ubl of ISG15 alone supports efficient ISG15 conjugation in cells (22) , demonstrating that the N-Ubl has little or no role in the conjugation steps catalyzed by the E1, E2, and E3 (Herc5) enzymes. Considering that the C-Ubl alone can function effectively with all three conjugation enzymes in cells, in order to understand how binding by NS1B inhibits ISG15 conjugation, it is important to determine if accessibility of the C-Ubl is affected by complex formation.
Although the crystal structures of both human ISG15 (2) and NS1B-NTR (residues 1-103) (23) have been determined individually, the structure of the complex formed between human ISG15 and NS1B-NTR has not been described previously. To elucidate the structural basis for the sequence-specific recognition of human ISG15, we determined the crystal structure of the complex formed between the NS1B-NTR and human ISG15. Coupled with mutagenesis experiments, the X-ray structure identifies the key residues in the NS1B-NTR constituting its two ISG15-binding sites. Interestingly, each of these two ISG15-binding sites is composed of residues in both chains in the NS1B-NTR dimer.
Most importantly, the crystal structure reveals the structural basis for the sequence-specific binding of human ISG15 by the NS1B-NTR; the primary contact region of NS1B-NTR on ISG15 includes residues in the linker connecting the two Ubl domains that are specific for human and nonhuman primate ISG15s. Further, the structure of the complex also identifies NS1B-NTR binding sites in the N-Ubl of ISG15 and shows that there are essentially no contacts of NS1B-NTR with the C-Ubl of ISG15, indicating that NS1B-binding to ISG15 should not occlude access of the C-terminal domain of ISG15 to its conjugating enzymes. This conclusion is supported by the report that the E1 and E2 enzymes function efficiently with full-length ISG15 when it is bound to NS1B (21) . Nonetheless, transfection assays demonstrate that binding of ISG15 by the NS1B-NTR domain is sufficient for the inhibition of IFN-induced ISG15 conjugation in cells. These observations lead us to propose that NS1B inhibits conjugation of ISG15 by sequestering the protein away from the sites of conjugation, rather than physical occlusion of specific interactions with conjugation enzymes.
Results and Discussion
The NS1B-NTR Binds Two ISG15 Molecules in the Crystal and also in Solution. The overall structure of the complex is shown in Fig. 1A . Crystallographic statistics are tabulated in Table S1 . The asymmetric unit consists of one NS1B-NTR dimer, composed of two NS1B-NTR chains (referred to as NS1B-NTR-A and NS1B-NTR-B), and two ISG15 molecules (referred to as ISG15-C and ISG15-D). The final refined model contains residues 7-101 in NS1B-NTR-A and residues 7-103 in NS1B-NTR-B, respectively, and residues 4-154 for both ISG15-C and ISG15-D, plus 142 water molecules.
The complex of NS1B-NTR with ISG15 is a hetero-tetramer, with the NS1B-NTR homodimer interacting with two ISG15 molecules, one on each side of the dimer (Fig. 1A) . The RBD (residues 15-90) of the NS1B-NTR homodimer has a structure that is very similar to that observed in the crystal structure of the RNA-binding domain of NS1B-NTR alone (23) . Each of the two ISG15 molecules (ISG15-C and ISG15-D) binds to a surface site on NS1B-NTR composed of residues from both of the two chains. The structural details at each of these two binding sites on NS1B-NTR for ISG15-C and ISG15-D are similar but not identical, as will be discussed below.
It was previously reported, based on gel filtration studies, that in solution one ISG15 molecule binds to the monomeric form of NS1B-NTR to form a heterodimer (21) . This report is difficult to reconcile with the well-known tight-binding of the two chains that comprise the comparable dimeric RBD of the NS1 protein of influenza A virus (NS1A protein) (24) . To resolve this apparent discrepancy, we used sedimentation equilibrium measurements to determine the mass and stoichiometry of the ISG15: NS1B-NTR complex in solution. First, sedimentation equilibrium was used to determine the oligomeric state of NS1B-NTR and ISG15 independently in solution (Fig. S1 ). The best fit for the sedimentation equilibrium profiles yielded a molar mass for ISG15 of 17,434 Da, which agrees with the calculated molar mass of an ISG15 monomer (18,056 Da), and a molar mass for NS1B-NTR of 26,366 Da, coinciding with the calculated molar mass of a NS1B-NTR homodimer (26, 198 Da) . In addition, a monomer-todimer equilibrium model yielded a dissociation constant (K d ) of ≪530 nM for NS1B-NTR homodimerization, verifying that NS1B-NTR forms a stable homodimer in solution. We next used sedimentation equilibrium to measure the stoichiometry of the complex formed by the reversible interaction of NS1B-NTR and ISG15 in solution. Details of these experiments are presented in the legend of Fig. S2 . The resulting sedimentation equilibrium profiles at three rotor speeds for each of five different concentrations of ISG15 were globally fitted to either an interaction of NS1B-NTR with one ISG15 molecule or with two ISG15 molecules. Only the later model fit the results, with a single dissociation constant of 1.9 μM (0.4 μM < K d < 4.0 μM). These results demonstrate that the stoichiometry of the complex in solution is 1 NS1B-NTR homodimer: 2 ISG15 molecules, as in the crystal structure shown in Fig. 1A . The NS1B-NTR dimer does not dissociate into its individual chains during ISG15 binding.
The Two Binding Sites on NS1-NTR for the Two ISG15 Molecules Are Similar but Not Identical. Our structure of the NS1B-NTR: ISG15 complex shows that one NS1B-NTR dimer interacts with two ISG15 molecules. The two ISG15-binding sites are independent of the dsRNA binding site and the nuclear localization sequence (Fig. 1B) . Each of the two ISG15 molecules binds to a surface site on NS1B-NTR composed of residues from both of the two chains. Each binding site includes residues in polypeptide segment 29-39, including the C-terminal end of helix α1 and the loop between helices α1 and α2 in the RBD from one NS1B-NTR chain, and residues of the other chain located mostly in polypeptide segment 84-100, including the C-terminal end of helix α3 in the RBD and the N-terminal portion of the interdomain linker region. The two ISG15 binding sites on the NS1B-NTR are illustrated in Fig. 1B . As shown for binding site 1 (Fig. 1C) , both binding sites include a deeper groove (in the 29-39 amino-acid region) and a shallower groove (in the 84-100 amino-acid region), into which portions of ISG15 are inserted.
The interactions between ISG15 and NS1B-NTR at each of the two NS1B-NTR binding sites are similar but not identical. One ISG15 molecule (ISG15-C) binds in site 1 to residues at the C-terminal end of helix α1 and in the α1-α2 loop of one NS1B-NTR chain (designated NS1B-NTR-B), and also to residues located in the other chain (NS1B-NTR-A), largely in the polypeptide linker following helix α3 (Fig. 2, Table 1 ). The primary contact region in NS1B-NTR-B is composed of residues 36-38, which form 4 hydrogen bonds and 29 van der Waals (vdW) contacts with ISG15-C. The second ISG15 molecule (ISG15-D) binds to the same regions on the opposite NS1B-NTR chains, but this binding site includes only a subset of the interactions observed in the otherwise symmetric binding site 1 (Table 1 and Fig. S3) . A detailed summary of the ISG15-binding interactions in site 1 and in site 2 are presented in the SI Text. Binding site 2 does not include interactions with residues E29, E32, R33, I97, G99, F100, and E101 of NS1B (Table 1 ). The electron densities of residues after P93 in NS1B-NTR-B are weak, and no contacts are observed between these C-terminal residues of site 2 and ISG15. There are also some differences in the intermolecular contacts and the local conformations of other NS1B residues, particularly Q37 in the interface (cf. Fig. 2 and Fig. S3 ). The total buried surface between NS1B-NTR and ISG15-C is 1;903 Å 2 , and the total buried surface between NS1B-NTR and ISG15-D is 1;361 Å 2 . Both ISG15-binding sites comprise a continuous surface on NS1B-NTR but are discontinuous in sequence and require the unique folding of the dimeric NS1B-NTR to be functional. The biological relevance of these differences between the two ISG15 binding sites is not known at present. One possibility is that the less extensive binding site 2 represents an intermediate state on the pathway to tighter binding. Another possibility is that binding of ISG15 to one site (site 1) results in an altered structure with reduced binding affinity for ISG15 at the second binding site (site 2)-i.e., negative cooperativity. However, as outlined above, the sedimentation equilibrium data can be fit using a single affinity constant for both binding sites.
Compared to the 1.98-Å crystal structure of the NS1B-NTR in its free form (23), there is little or no conformational change in the NS1B-RBD region of the NS1B-NTR upon ISG15 binding. The rmsd over 150 C α atoms (residues 16-90 in each monomer) between the ISG15-bound NS1B-NTR and unbound NS1B-NTR structures is only 0.585 Å. However, there are some significant structural differences in both N-and C-terminal regions of the NS1B-NTR, especially in the short C-terminal polypeptide segment that follows helix α3, which appears to be flexible in the free NS1B-NTR structure and becomes ordered as a result of its binding to ISG15. This disorder-to-order transition of the interdomain linker region on NS1B provides an entropic modulation of the binding affinity.
Validation of the ISG15-Binding Site by Site-Directed Mutagenesis of
Full-Length NS1B. The crystal structure shows that each of the two ISG15 molecules bind to a surface site on the NS1B-NTR homodimer composed of residues from both of its two chains. To determine whether these interactions with residues in both chains of NS1B-NTR are in fact required for binding an ISG15 molecule in human cells, we carried out GST pulldown assays. Human 293Tcells were transfected with a plasmid expressing GST-tagged human ISG15 along with a plasmid expressing either WT or mu- tant full-length NS1B proteins (residues 1-281). As a control, a plasmid expressing the GST tag alone was also coexpressed with a plasmid expressing the full-length NS1B protein. Cell extracts were subjected to glutathione Sepharose selection, and GSTcontaining protein complexes were eluted with glutathione and analyzed by immunoblots probed with antibody against the NS1B protein (Fig. 3) . Two mutant NS1B proteins were tested. In one mutant protein, residues 36 and 37 were changed to alanines (lane 3). This mutant protein did not bind to human ISG15, establishing that residues at the C-terminal end of helix α1 and in the α1-α2 loop in the NS1B-RBD are required for binding human ISG15. Similarly, a full-length NS1B protein with two alanine substitutions simultaneously at positions 91 and 100 exhibited little or no binding to human ISG15 (lane 4), validating that this part of the ISG15-binding site, corresponding to the interdomain linker region of NS1B, is also required for binding. These studies confirm that residues from both of the two NS1B chains are required for binding ISG15 in human cells.
The Binding Site for NS1B-NTR on Human ISG15 Includes Residues in the Linker Region That Are the Required Determinants of Species
Specificity. At ISG15-binding site 1 NS1-NTR interacts with two regions of human ISG15-C (Fig. 4A) , which form a continuous surface (Fig. 4B) . The primary contact region is composed of residues at the junction of the N-Ubl and the linker region, specifically atoms of residues in polypeptide segment 72-77. This region of ISG15 forms 5 hydrogen bonds and 59 vdW contacts with the NS1B-NTR, which are actually more than are formed by the main body of the N-Ubl (Table S2 ). The second contact region is within the main body of the N-Ubl, where the largest contact surface includes atoms of residues 8-12 in the β1/β2 loop (indicated in Fig. 4C ) that inserts into the deep groove of the ISG15-binding sites on the NS1B-NTR dimer. Many vdW contacts are also contributed by atoms in polypeptide segment residues 36-49. Although the second ISG15 molecule (ISG15-D) bound at site 2 of NS1B-NTR (NS1B-NTR-A) has fewer interactions, the general pattern of contacting residues are the same as observed for ISG15-C at site 1. However, in binding site 2 ISG15-D has an additional vdW contact with NS1B-NTR via residue 51 (Table S2 ).
The sequence of ISG15 varies between species. The NS1B protein binds only human and nonhuman primate ISG15 molecules (16) . Fig. 4D shows the alignment of ISG15 molecules of four species, two of which, hu (human) and agm (African green monkey), bind to the NS1B protein; and two of which, mo (mouse) and ca (canine), do not bind to the NS1B protein. The 5-residue interdomain linker region between the two Ubl domains (residues 76-80) in human and nonhuman primate ISG15 molecules is crucial for the binding to the NS1B protein. Replacement of individual residues in the human linker with their mouse counterpart (D76Q, K77N, D79S) eliminated binding of human ISG15 to the NS1B protein (16) . These mutagenesis experiments could not determine the role of the human interdomain linker sequence in NS1B binding-i.e., whether it is required to provide the proper orientation of the N-Ubl for its binding to the NS1B protein, or whether residues in this interdomain linker region directly interact with residues in the NS1B protein. The crystal structure of the NS1B-NTR: ISG15 complex establishes that the first two residues in the human linker region (D76 and K77) interact directly with NS1B residues (Table 1, Fig. 2 ). For example, K77 forms 3 salt bridges and 16 vdW contacts with residues in binding site 1 of NS1B-NTR. No interactions were detected between NS1B-NTR and residue 79 of the interdomain linker, which is also different between hu/agm and mo/ca (Fig. 4D) .
The previous mutagenesis experiments indicated that there was an additional binding site in the N-Ubl that was shared by human, nonhuman primate, and canine ISG15s, but not by mouse A HB vdW ISG15-D   E29  2  3  K77  E32  1  1  K77  R33  1  K77  F34  2  L10  F34  2  L10  W36  1  Q42  W36  2  V75  5  V75  2  D76  10  K77  10  K77  1  T101  Q37  4  V74  Q37  1  M9  3  L 1 0  2  6  V75  2  6  V75  R38  2  2  I36  R38  2 
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HB: hydrogen bonds; SB: salt bridges; vdW: van der Waals contacts. vdW contact distance cut-off (Å): C-C, 4.1; C-O, 3.7; C-N, 3.8; N-N, 3.4; N-O, 3.4; O-O, 3.3. Fig. 3 . Residues in both NS1B-NTR chains are required for binding ISG15 in human cells. Human 293T cells were transfected for 36 hours with the indicated plasmids as described in the text. Cell extracts were subjected to glutathioneSepharose selection, and the eluents were analyzed by immunoblots (WB) using anti-NS1B or anti-GST antibody. Aliquots of cell extracts were analyzed by an immunoblot using anti-NS1B antibody to ensure that equivalent amounts of NS1B-NTR were produced in all the transfections.
ISG15 (16) . However, because these experiments did not identify this binding site, it was not possible to deduce the features of the N-Ubl of mouse ISG15 that prevent binding. The crystal structure reveals that residues 8-12, together with residue I36, make the largest number of contacts with NS1B-NTR residues. The amino-acid sequence of mouse ISG15 in these regions is identical to that of monkey ISG15 (Fig. 4D) , indicating that these regions in mouse ISG15 do not contribute to its defect in binding to NS1B. However, the crystal structure shows that atoms in residues within polypeptide segment 38-51 in human ISG15 make several vdW contacts with NS1B-NTR. Mouse ISG15 has sequence differences, as well as two deletions, in the region from 47-52, compared with the human, monkey, and canine ISG15 sequences (Fig. 4D) . This suggests that interactions with residues in this polypeptide segment, located at the C-terminal end of strand β3 and the N-terminal end of the loop between strand β3 and 3 10 -helix η2, contribute to the sequence-specific recognition of human and nonhuman primate ISG15s, relative to mouse ISG15.
Structural comparison of the N-Ubls of free and NS1B-NTR bound ISG15 indicates modest structural changes upon NS1B-NTR binding (Fig. S4 C and D) , with backbone rmsds for residues 4-75 between free and bound forms of 1.05 and 0.96 Å for ISG15-C and ISG15-D, respectively. In addition, the relative orientations of the two Ubl domains of ISG15 are slightly different in the complex compared to the unbound ISG15 in its reported crystal form (Fig. S4 A and B) , with backbone rmsds for residues 4-154 of 2.32 and 2.47 Å for ISG15-C and ISG15-D, respectively. These differences in relative orientations of the two Ubl domains may reflect a small change in orientation relative to the unbound solution state upon complex formation, due in part to the specific interactions between NS1B and the interdomain linker region of ISG15. Alternatively, they may simply reflect the constraints of crystal packing that can stabilize different interdomain orientations in crystals of the complex compared with crystals of free ISG15, as in the crystal lattice each of the two ISG15 molecules in each unit cell contacts an ISG15 molecule of an adjacent unit cell. In either case, the variations in interdomain orientation observed in these crystal structures supports the view that the interdomain linker of ISG15 is intrinsically flexible but becomes ordered upon binding to NS1B. This disorder-to-order transition of at least part of the interdomain linker of ISG15 also contributes an entropic component to the free energy of complex formation.
There is only a single vdW contact of NS1B-NTR with the CUbl of human ISG15, involving residue T101 in the N-terminal region of this Ubl domain. In addition, the structures of the C-Ubls (residues 81-152) of free ISG15 and ISG15 bound to the NS1B-NTR are essentially identical, with rmsds of 0.30 and 0.31 Å for ISG15-C and ISG15-D, respectively (Fig. S4 A and B) . Overall, the structure of the complex (Fig. 1A) indicates that NS1B-binding to ISG15 is not expected to occlude access of the C-terminal domain of ISG15 to the conjugating enzymes.
Mutational Inactivation of the ISG15-Binding Site in the NS1B Protein Eliminates Its Suppression of IFN-Induced ISG15 Conjugation, As Assayed in Transfection Experiments. It has been established that the full-length NS1B protein inhibits ISG15 conjugation, as assayed in transfection experiments (17, 21) . To determine whether the NS1B-NTR, which contains the binding sites for ISG15, inhibits IFN-induced ISG15 conjugation as effectively as the full-length NS1B protein, we carried out transfection experiments in human HeLa cells, as described in SI Materials and Methods. As shown in Fig. 5A , full-length NS1B and NS1B-NTR suppressed 24 hours with a plasmid expressing 3xFlag and, where indicated, a plasmid expressing either full-length NS1B or NS1B-NTR. Where indicated, the cells were then treated with 1;000 units∕mL of IFN-β for 24 hours. Cell extracts were analyzed by immunoblots using either anti-Flag antibody to measure free ISG15 and ISG15 conjugates, anti-NS1B antibody to measure the levels of full-length NS1B or NS1B-NTR expression, or antitubulin antibody as a loading control. (B) 293T cells were transfected for 24 hours with a plasmid expressing 3xFlag and, where indicated, a plasmid expressing either wt NS1B or NS1B with alanines at positions 36 and 37. Where indicated, the cells were then treated with 1;000 units∕mL of IFN-β for 24 hours. Cell extracts were analyzed by immunoblots as described for panel A.
IFN-induced ISG15 conjugation to similar extents (lanes 3 and 4) , indicating that the effector domain of the NS1B protein plays little or no role in the inhibition of IFN-induced ISG15 conjugation.
To determine whether the ISG15-binding site on NS1B is required for the inhibition of IFN-induced ISG15 conjugation, human cells (293T cells) were cotransfected with a plasmid expressing 3xFlag-ISG15 and a second plasmid expressing either wild-type (WT) full-length NS1B or full-length NS1B with a mutated ISG15-binding site (i.e., W36A/Q37A). As a control, another set of cells was transfected with only the plasmid expressing 3xFlag-ISG15. As shown in Fig. 5B , the WT NS1B protein efficiently suppressed IFN-β induced ISG15 conjugation (lane 3). In contrast, the NS1B protein with a mutated ISG15-binding site lost most of the ability to suppress ISG15 conjugation (lane 4). We conclude that the ISG15-binding site on the NS1B protein identified in our crystal structure of the NS1B-NTR: ISG15 complex is required for the inhibition of IFN-induced ISG15 conjugation in human cells.
Why does the binding of ISG15 by the NS1B protein lead to the inhibition of ISG15 conjugation in cells? There is only a single vdW contact of NS1B-NTR with the C-Ubl of human ISG15 (Table 1) , and the structures of the C-Ubls of free and NS1B-NTR bound ISG15 are essentially identical ( Fig. S4 ; SI Results and Discussion). The structure of the complex (Fig. 1A) indicates that NS1B-binding to ISG15 would not occlude access of the Cterminal domain of ISG15 to the conjugating enzymes. In fact, the E1 and E2 enzymes function efficiently with the full-length ISG15 protein even when it is bound to the NS1B protein (21) . A predicted model of the ISG15-UbE1L complex (2) also locates the E1 conjugating enzyme in a region of the ISG15 C-terminal domain that is distant from the NS1B-binding sites in the N-terminal and linker domains of ISG15 identified in our crystal structure. In addition, the C-Ubl by itself also supports efficient ISG15 conjugation in human cells, as assayed by transfection experiments (22) , showing that the N-Ubl has little or no role in the conjugation steps catalyzed by not only the E1 and E2 enzymes but also the E3 (Herc5) ligase. This result indicates that the Herc5 enzyme may be expected to function with the C-Ubl in an ISG15: NS1B complex, but this prediction cannot be tested at present because a functional Herc5 enzyme is not currently available.
One possible mechanism by which NS1B-binding suppresses ISG15 conjugation is that binding of ISG15 to NS1B does not impose a structural impediment to conjugation but instead leads to the sequestration of ISG15 away from the cellular sites at which conjugation occurs. This mechanism is consistent with recent reports that ISG15 conjugation targets newly synthesized proteins and hence occurs on polyribosomes (22) . However, in human cells transfected with a plasmid expressing the NS1B protein, and also in influenza B virus-infected human cells, the NS1B protein relocalizes essentially all the ISG15 from the cytoplasm to intranuclear compartments known as splicing or S35 speckles (16, 25) . Consequently, little or no ISG15 would be available for polyribosome-associated ISG15 conjugation. Future experiments will test this possibility.
The present results reveal how the NS1B protein of influenza B virus recognizes and binds only human and nonhuman primate ISG15 molecules: The major contact site of NS1B with human ISG15 includes the first two N-terminal residues of the linker region, which are specific for the ISG15s of these species. Because the NS1B protein would not protect influenza B virus from the antiviral effects of interferon-induced ISG15 and ISG15 conjugation in other mammalian species, this virus would not be expected to be maintained in these species.
Materials and Methods
Human ISG15 and NS1B-NTR were cloned into pMBP and pET15b expression vectors (Novagene), respectively, and expressed in Escherichia coli as described in SI Materials and Methods. The individually purified proteins were then mixed to form the complex, which was further purified by gel filtration. Detailed procedures are outlined in SI Materials and Methods. The complex was crystallized in 15% PEG 3350 with 1% dioxane, and diffraction data were collected and processed as described in SI Materials and Methods. The structure of the complex was determined by molecular replacement and refined at 2.3 Å to final R work and R free of 22.2% and 26.1%, respectively. Details of X-ray crystallography methods, sedimentation equilibrium experiments, and transfection assays are described in SI Materials and Methods.
